SG11202011227VA - Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof - Google Patents
Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereofInfo
- Publication number
- SG11202011227VA SG11202011227VA SG11202011227VA SG11202011227VA SG11202011227VA SG 11202011227V A SG11202011227V A SG 11202011227VA SG 11202011227V A SG11202011227V A SG 11202011227VA SG 11202011227V A SG11202011227V A SG 11202011227VA SG 11202011227V A SG11202011227V A SG 11202011227VA
- Authority
- SG
- Singapore
- Prior art keywords
- bisfluoroalkyl
- compositions
- methods
- benzodiazepinone compounds
- benzodiazepinone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862671748P | 2018-05-15 | 2018-05-15 | |
PCT/US2019/032326 WO2019222298A1 (en) | 2018-05-15 | 2019-05-15 | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202011227VA true SG11202011227VA (en) | 2020-12-30 |
Family
ID=68540867
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202011227VA SG11202011227VA (en) | 2018-05-15 | 2019-05-15 | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210220372A1 (en) |
EP (1) | EP3793563A4 (en) |
JP (1) | JP2021523189A (en) |
KR (1) | KR20210008527A (en) |
CN (1) | CN112236147A (en) |
AU (1) | AU2019271151A1 (en) |
BR (1) | BR112020023204A2 (en) |
CA (1) | CA3100202A1 (en) |
MX (2) | MX2020012281A (en) |
SG (1) | SG11202011227VA (en) |
WO (1) | WO2019222298A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019215585A1 (en) * | 2018-05-06 | 2019-11-14 | Ayala Pharmaceuticals Inc. | Compositions comprising cd20 inhibitors and bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof |
JP2021526517A (en) * | 2018-05-24 | 2021-10-07 | アヤラ ファーマシューティカルズ インコーポレイテッド | Compositions containing bisfluoroalkyl-1,4-benzodiazepinone compounds and immunotherapeutic agents and methods of their use |
SG11202112061RA (en) * | 2019-05-15 | 2021-11-29 | Ayala Pharmaceuticals Inc | Bisfluoroalkyl-1,4-benzodiazepin one compounds for treating notch-activated breast cancer |
US20230047191A1 (en) * | 2021-08-05 | 2023-02-16 | Celanese Eva Performance Polymers Llc | Implantable Medical Device for the Delivery of Bisphosphonate |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0025173D0 (en) * | 2000-10-13 | 2000-11-29 | Merck Sharp & Dohme | Therapeutic agents |
PT1673347E (en) * | 2003-10-06 | 2015-11-02 | Hoffmann La Roche | Substituted dibenzo-azepine and benzo-diazepine derivatives useful as gamma-secretase inhibitors |
CA2644136A1 (en) * | 2006-02-27 | 2007-09-07 | The Johns Hopkins University | Cancer treatment with gamma-secretase inhibitors |
TWI530489B (en) * | 2011-03-22 | 2016-04-21 | 必治妥美雅史谷比公司 | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds |
TWI614238B (en) * | 2012-09-21 | 2018-02-11 | 必治妥美雅史谷比公司 | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds and prodrugs thereof |
US9492469B2 (en) * | 2013-04-04 | 2016-11-15 | Bristol-Myers Squibb Company | Combination therapy for the treatment of proliferative diseases |
CN115554406A (en) * | 2016-01-07 | 2023-01-03 | 博笛生物科技有限公司 | anti-CD 20 combinations for the treatment of tumors |
-
2019
- 2019-05-15 KR KR1020207035898A patent/KR20210008527A/en not_active Application Discontinuation
- 2019-05-15 JP JP2020563971A patent/JP2021523189A/en active Pending
- 2019-05-15 MX MX2020012281A patent/MX2020012281A/en unknown
- 2019-05-15 CN CN201980037038.7A patent/CN112236147A/en active Pending
- 2019-05-15 US US17/055,602 patent/US20210220372A1/en active Pending
- 2019-05-15 BR BR112020023204-1A patent/BR112020023204A2/en unknown
- 2019-05-15 EP EP19802870.6A patent/EP3793563A4/en active Pending
- 2019-05-15 AU AU2019271151A patent/AU2019271151A1/en active Pending
- 2019-05-15 CA CA3100202A patent/CA3100202A1/en active Pending
- 2019-05-15 WO PCT/US2019/032326 patent/WO2019222298A1/en unknown
- 2019-05-15 SG SG11202011227VA patent/SG11202011227VA/en unknown
-
2020
- 2020-11-13 MX MX2024007360A patent/MX2024007360A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210008527A (en) | 2021-01-22 |
WO2019222298A1 (en) | 2019-11-21 |
US20210220372A1 (en) | 2021-07-22 |
JP2021523189A (en) | 2021-09-02 |
MX2020012281A (en) | 2021-01-29 |
AU2019271151A2 (en) | 2021-01-14 |
CA3100202A1 (en) | 2019-11-21 |
AU2019271151A1 (en) | 2021-01-07 |
EP3793563A4 (en) | 2022-02-23 |
CN112236147A (en) | 2021-01-15 |
MX2024007360A (en) | 2024-06-28 |
EP3793563A1 (en) | 2021-03-24 |
BR112020023204A2 (en) | 2021-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202007838B (en) | Polymerases, compositions, and methods of use | |
ZA202007839B (en) | Polymerases, compositions, and methods of use | |
IL277079A (en) | Cartyrin compositions and methods for use | |
IL274276A (en) | Casz compositions and methods of use | |
IL280963A (en) | Anti-gdf15 antibodies, compositions and methods of use | |
IL278829A (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and immunotherapeutics and methods of use thereof | |
GB2582100B (en) | CAS12C Compositions and methods of use | |
IL288278A (en) | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | |
PL3557998T3 (en) | Compouns, compositions and methods of use | |
EP3576782A4 (en) | Construct-peptide compositions and methods of use thereof | |
HK1259372A1 (en) | Therapeutic compounds, compositions and methods of use thereof | |
ZA201906169B (en) | Synthekine compositions and methods of use | |
IL283968A (en) | Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | |
IL276135A (en) | Compositions and methods of use | |
IL282939A (en) | Mixtures and compositions comprising 5-fluoro-4-imino-3- methyl-1-tosyl-3,4- dihydropyrimidin-2-one, and methods of use thereof | |
EP3697791A4 (en) | Heterocyclic compounds, compositions comprising heterocyclic compound, and methods of use thereof | |
IL283387A (en) | Diarylhydantoin compounds and methods of use thereof | |
ZA202100780B (en) | Bismuth-thiol compositions and methods of use | |
IL277786A (en) | Aav compositions, methods of making and methods of use | |
SG11202011227VA (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | |
SG11202011041YA (en) | Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof | |
HK1258765A1 (en) | Therapeutic compounds, compositions and methods of use thereof | |
EP3426238A4 (en) | Curcumin-based compositions&methods of use thereof | |
EP3735246A4 (en) | Mito-lonidamine, compositions and methods of use | |
GB201808668D0 (en) | Compounds and compositions and uses thereof |